ClinicalTrials.gg
RecruitingNCT07136740BioTenCerUpdated Jul 21, 2026

BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache

An interventional study of Cerebri-TTH biofeedback and headache diary in Tension Type Headache, sponsored by Helse Nord-Trøndelag HF. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Helse Nord-Trøndelag HF · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test a therapist-independent home-based smartphone app-based biofeedback treatment in adults with tension type headache. The aim of the study is to assess the safety and performance of the Cerebri-TTH biofeedback device as a preventive treatment in adults with frequent and chronic tension type headache.

The primary endpoint of the study is the change in the mean Area-Under-the-headache-Curve (AUC) from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the placebo group.

Read the detailed description

This trial, BioTenCer, is a clinical study to test the efficacy and safety of the app-based biofeedback treatment, Cerebri-TTH, for tension type headache in adults. Bodily signals that are thought to be associated with TTH are measured by sensors during biofeedback. During the treatment, one sensor is placed on the skin above the upper trapezius muscle fibers to measure shoulder and neck muscle tension and one sensor is attached to the index finger to measure peripheral skin temperature and heart rate variability. By getting on-screen feedback on the phone, the user can learn techniques to reduce muscle tension, and increase finger temperature and heart rate variability. Reduced muscle tension, as well as an increase in finger temperature and heart rate variability is a sign of relaxation and a deactivation of the autonomous nervous system, which can lead to less intensity and fewer days of TTH. The aim of the study is to investigate the safety and efficacy of biofeedback treatment using Cerebri-TTH compared to wait-list controls. In this study, the investigators will randomize 300 adults with frequent and chronic TTH. All participants will complete a minimum of 4 weeks of daily headache diary entries in the Cerebri-TTH app. This will serve as the "baseline" measurements. Subsequently, the participants will be randomized to either the treatment group or the wait-list group. The treatment group will conduct daily biofeedback sessions (one session has a duration of 10 minutes) for 12 weeks. The wait-list group does not receive any specific treatment for 12 weeks but serves as an important basis for comparison to evaluate the treatment effect. The wait list control group will be offered active treatment for 12 weeks after the initial 12-week wait-list period is completed in an extension phase. Similarly, the intervention arm can contribute with an additional 12 weeks of eDiary recordings if they are willing. Participants in both groups (the treatment group and the wait-list control group) must complete daily registrations in the headache diary included in the app. The primary endpoint of the study is the change in the mean Area-Under-the-headache-Curve (AUC) from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the placebo group. AUC is calculated from a curve of the duration and intensity of headaches. Secondary key endpoints include the change in intensity of TTH, the change in duration of TTH, the change in mean number of days with TTH, the change in consumption of acute medication for TTH and the number, of participants with at least 30%, 50%, 75% and 100% reduction in mean Area-Under-the headache Curve (AUC). Preventive treatments for TTH, both drug and non-drug, have limited effects and potentially numerous side effects. If the biofeedback app proves to be effective, it may represent a useful and viable treatment option for TTH patients, that is readily available and unlikely to cause unwanted side effects.

Number of Participants: the investigators will randomize 300 adult patients with TTH, with 150 participants randomized to each arm.

The study consists of two arms. There is a run-in screening period of 4 weeks for both arms, and a treatment/waitlist period of 12 weeks. Subsequently, an extended treatment period of 12 weeks is offered to the waitlist control group. The participants in the treatment are arm are asked to contribute to an additional 12 weeks of daily eDairy registration explore the headache status and safety aspects after ended biofeedback training. The total duration of study participation for each participant is 16 weeks for the intervention arm and for the wait-list control arm which includes the screening/inclusion visit, a run-in period of 4 weeks without study intervention, a 12-week treatment/waitlist period with 3 planned telephone follow-ups before a final visit. An additional 12 weeks extension is offered participants, and in such cases the final visit is placed at the end of the extension phase. Subjects will complete daily app-based biofeedback sessions of 10 minutes per session for 12 weeks as the study intervention

02

Conditions studied

  • Tension Type Headache

Browse trials for

Keywords

  • biofeedback
  • tension type headache
  • therapist independent treatment
03

In context

Tension-Type Headache

144 studies on the registry are indexed under Tension-Type Headache; 42 are open to participants now.

This study's planned enrollment of 300 is above the median of 60 across 109 interventional studies indexed under Tension-Type Headache.

Browse Tension-Type Headache studies →

Lead sponsor

Helse Nord-Trøndelag HF is the lead sponsor of 27 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age inclusive or older, at the time of signing the .
  • A diagnosis of TTH according to the criteria of the International Classification of Headache Disorders 3rd edition (ICHD-3)
  • History of at least 6 days or more with TTH per 28-day period in the 3 months prior to screening (as recalled by the subject).
  • Frequency of at least 6 days or more with TTH per 28-day period, confirmed by daily diary entries in the baseline period.
  • At least three months of experience with smartphone and access to an iOS or Android phone at home.
  • Capability of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Onset of TTH (and migraine, if present) before the age of 50 years.
  • The onset of TTH should be present for at least 1 year prior to inclusion.

Exclusion criteria

Exclusion Criteria:

  • Subject does not master a Scandinavian language at a level sufficient to fully understand the written and verbal study information.
  • Subject is unable to differentiate TTH from other concomitant headaches.
  • A history of more than 1 migraine attack per month on average in the last year, as recalled by the patient.
  • Frequency of more than 1 migraine attack per month during the baseline period, as confirmed by daily diary entries.
  • Subjects diagnosed with trigeminal autonomic cephalalgias and cranial neuralgias.
  • Subjects with secondary headache conditions with the exception of medication overuse headache (MOH) as defined in the ICHD-3 criteria that undergo a successful 8 weeks acute medication stop, and does not overuse medication in the following 28 day period.
  • Use of concurrent TTH preventive medication, with the exception of stable dose (≥3 months or 5 half-lives, whichever is longer) monotherapy of TTH preventive medication.
  • Use of prophylactic medication with known prophylactic effect on other headache disorders, whatever the indication, with the exception of stable dose (≥3 months or 5 half-lives, whichever is longer) monotherapy of any preventive medication.
  • Subjects taking opioids (>3 days per month) or barbiturates at the time of screening.
  • Reduced sensibility, hearing or vision to a degree that impairs proper use of the app.
  • Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator.
  • Patients exhibiting a high degree of comorbidity and/or frailty associated with reduced or high likelihood of hospitalization, at the discretion of the investigator.
  • Use of non-pharmacological preventive treatment, that in the opinion of the investigator is likely to interfere with the evaluation of the biofeedback treatment strategy under investigation. Stable non-pharmacological treatments for other indications than TTH that is not likely to interfere, is allowed if it is kept unaltered during study participation.
  • Previous or current use of biofeedback equipment.
  • Other pain conditions, not intended to be treated in this study, that in the opinion of the investigator could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints
  • High probability neurological deterioration due to other medical conditions, that in the opinion of the investigator may confound outcome assessment.
  • Have within 6 months of enrolment a significant untreated addiction to dependency-producing medications, alcohol, or illicit drugs.
  • Abnormal pain behaviour, inappropriate medication-use and/or unresolved psychiatric illness, that in the opinion of the investigator are significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.
  • Subject is currently participating or planning to participate in another clinical investigation.
  • Subject who is unlikely to follow Clinical Investigation Plan or where treatment seems futile in the opinion of the Investigator or have demonstrated an inability to sufficiently adhere to headache diary entries (\<70%).

This study excludes patients with more than 1 migraine attack per month. A migraine attack is defined according to ICHD-3 criteria as attacks of unilateral, pulsating, moderate or severe headache lasting 4-72 hours that is aggravated by physical activity, associated with nausea and/or photophobia and phonophobia, and, in some cases, preceded by unilateral, fully-reversible central nervous system symptoms.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Treatment group is randomized to receive biofeedback treatment for 12 weeks. The intervention arm- treatment-group will be offered contribute with in an extension phase: an additional 12 weeks of eDiary recordings if they are willing.

    Device: Cerebri-TTH biofeedback · Other: headache diary

  • Placebo comparator
    wait-list group

    The wait-list group does not receive any specific treatment for 12 weeks but serves as an important basis for comparison to evaluate the treatment effect. This group will keep daily headache diary for 12 weeks. placebo group will be offered Cerebri-TTH biofeedback in extension phase.

    Other: headache diary

Interventions

  • DeviceCerebri-TTH biofeedback

    Cerebri-TTH biofeedback device is a therapist-independent home-based smartphone treatment application (app). Cerebri-TTH is a medical device in risk class IIa, according to MDR, and includes two non-invasive wireless sensors and a smartphone application. Both sensors shall be in contact with the skin: one sensor is applied on the index finger and measures heart rate (HR), heart rate variability (HRV) and peripheral skin temperature. The second sensor is applied on the trapezius muscle using adhesive electrodes and measures muscle tension. The sensors transmit the measurements to the user's smartphone where the user is instructed to perform a biofeedback session. The sensors are to be used for 10 minutes per session per day. The user can choose to use the device more frequently if desired - up to 6 sessions per day.

  • Otherheadache diary

    Participants randomized to the wait-list arm, are instructed to keep daily eDairy entries for 12 weeks. The wait list control group will be offered active treatment for 12 weeks after the initial 12-week wait-list period is completed in an extension phase.

06

What researchers measure

Primary outcomes

  1. To investigate the efficacy of Cerebri-TTH in treatment group as compared to wait list control group in reducing the area under-the-headache curve (AUC)

    Difference in the mean AUC from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group

    Time frame: From day 1 up to 38 weeks.

  2. To describe the treatment-emergent adverse events encountered during the investigation (include treatment emergent adverse events, ADEs, SADEs, and USADEs).

    A description of the frequency and severity of treatment- emergent adverse events, ADEs, SADEs, and USADEs).

    Time frame: From randomization day-1 up to 34 weeks.

Secondary outcomes

  1. To investigate the efficacy of Cerebri-TTH in treatment group as compared to wait list control group in reducing the number of TTH days

    Difference in number of days with TTH per 4 weeks in the baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group

    Time frame: From day 1 up to 38 weeks.

  2. To investigate the efficacy of Cerebri-TTH in treatment group as compared to wait list control group in reducing mean headache intensity

    Difference in mean headache intensity from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  3. To investigate the efficacy of Cerebri-TTH in treatment group as compared to wait list control group in reducing mean headache duration.

    Difference in mean headache duration from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  4. To investigate the efficacy of Cerebri-TTH in treatment group as compared to wait list control group in reducing the use of rescue medication

    Difference in use of rescue medication from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group

    Time frame: From day 1 up to 38 weeks.

  5. To investigate patient-reported impact of headaches and headache treatment in the treatment group as compared to the control group.

    Difference in mean HURT-3 score in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  6. To investigate patient-reported symptoms of anxiety and depression in the treatment group as compared to the control group.

    Difference in mean Hospital Anxiety and Depression score (HADs) in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  7. To investigate the proportion of participants with at least 30% reduction in TTH duration and/or intensity from baseline to treatment between the treatment and control groups.

    Difference in number of treatment responders (≥ 30% reduction in the mean AUC) from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group

    Time frame: From day 1 up to 38 weeks.

  8. To determine the frequency of device deficiencies

    Occurrence of device deficiencies.

    Time frame: From randomization day 1 up to 34 weeks.

  9. Determine fetal outcome and the frequency of pregnancy complications

    Occurrence of pregnancy complications and report fetal outcome data

    Time frame: From day 1 up to 38 weeks.

Other outcomes

  1. To investigate the proportion of participants with at least 50% reduction in TTH duration and/or intensity from baseline to treatment between the treatment and control groups.

    Difference in number of treatment responders (≥ 50% reduction in the mean AUC)from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  2. To investigate the proportion of participants with at least 75% reduction in TTH duration and/or intensity from baseline to treatment between the treatment and control groups

    Difference in number of treatment responders (≥ 75% reduction in the mean AUC) from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  3. To investigate the proportion of participants with at least 100% reduction in TTH duration and/or intensity from baseline to treatment between the treatment and control groups

    Difference in number of treatment responders (100% reduction in the mean AUC) from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the wait-list control group.

    Time frame: From day 1 up to 38 weeks.

  4. Patient preference for treatment

    12 weeks post-intervention the participant is asked to rate a benefit/tolerability ratio on an 11 point NRS scale. Similarly, a benefit/feasibility score will be assessed on a similar 11 point scale

    Time frame: From day 1 up to 38 weeks.

  5. To explore the effect of the treatment on patients self-reported sleep quality.

    Difference in Bergen insomnia scale score (BIS) in the treatment group as compared to the wait-list control group. Participants state the number of days in which they experienced various sleep problems in the last month between 0 and 7 on an 8-point scale. The lowest score that can be taken from the scale is 0 and the highest score is 42.

    Time frame: From day 1 up to 38 weeks.

  6. To explore headache status in the 12 week extension period after completed 12 week biofeedback treatment

    Development in headache endpoint variables in the 12 week eDiary extension period

    Time frame: From day 1 up to 38 weeks.

  7. To explore efficacy combining biofeedback arm and extension biofeedback arm data

    Combined change in headache endpoint variables from baseline (last 28 period) before biofeedback treatment

    Time frame: From day 1 up to 38 weeks.

  8. To assess the subjective perception of treatment effectiveness from the patient's perspective.

    Change in PGI-C at week 4, 8 and 12 in the intervention arm.

    Time frame: From randomization day 1 up to 34 weeks

  9. To evaluate the level of perceived stress experienced by participants

    Mean change in PSS-14 total score from baseline to week12.

    Time frame: From day 1 up to 38 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 50 non-industry interventional studies with no phase under Tension-Type Headache, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 32. This study's planned 26 months is above that.

Counting every sponsor, half of 50 studies reached it within 9 months; a quarter within 3 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Aug 22, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136740
Lead sponsor
Helse Nord-Trøndelag HF
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Oct 17, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Tore Wergeland Meisingset, MD, PhD, Assc. Prof
Contact
tore.w.meisingset@ntnu.no
+4747358725
Kristina Devik, MD
Contact
kristina.devik@helse-nordtrondelag.no
+4798833255
Tore Wergeland Meisingset, MD, PhD, Assc. Prof.
principal investigator · Helse Nordtrøndelag Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion